Finally, A REMS FDA Could Live With
This article was originally published in Pharmaceutical Approvals Monthly
"It took us three months" to negotiate with FDA on the fine points of the REMS and make the refinements required to finalize the document, Amgen safety exec Rekha Garg told the recent Post-Approval Summit at Harvard.
You may also be interested in...
The Risk Evaluation and Mitigation Strategy for Amgen's platelet producer Nplate mandates enrollment at three levels of a controlled distribution system: institutions, physicians and patients
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011